Editor: What To Know
- “With more than 10,000 patients treated worldwide, we believe this is only the beginning, as CardioFocus is positioned to become a dominant force in the rapidly growing AFib ablation market with our proven HeartLight X3 System.
- CardioFocus is celebrating the treatment of the 10,000th patient by thanking the countless researchers, scientists, clinicians, suppliers, vendors, partners, investors, and employees (both past and present) that helped develop the HeartLight System.
- “The speed, control, predictability, and durability of HeartLight X3 are unparalleled and allow us to customize the treatment based on the unique needs of each patient.
December 15, 2020
CardioFocus HeartLight System is a revolutionary catheter ablation technology for controlled and consistent pulmonary vein isolation (PVI), the gold standard treatment for AFib. HeartLight is a treatment option for some patients whose AFib is insufficiently controlled with medication1.
CardioFocus is celebrating the treatment of the 10,000th patient by thanking the countless researchers, scientists, clinicians, suppliers, vendors, partners, investors, and employees (both past and present) that helped develop the HeartLight System.
Extensive clinical studies of the HeartLight System and the new HeartLight X3 System demonstrated that AFib patients can be treated quickly and with excellent procedure time predictability.2 In May of this year, the U.S. Food and Drug Administration (FDA) approved the next-generation HeartLight X3 System. This third-generation HeartLight X3 System offers a unique RAPID mode, which includes precise motor control that enables uninterrupted, high-speed, circumferential lesion creation under direct visual control of the physician resulting in consistently reduced procedure times.3
“As an early adopter of the HeartLight System, I have seen firsthand the benefits this transformational technology provides AFib patients,” said Henry D. Huang, M.D., a cardiac electrophysiologist at Rush University Medical Center in Chicago. “The speed, control, predictability, and durability of HeartLight X3 are unparalleled and allow us to customize the treatment based on the unique needs of each patient.”
More than 33 million patients worldwide suffer from AFib,4 which has been associated with significant symptoms, functional impairment, stroke, cognitive decline, heart failure, and reduced longevity.
“We are committed to providing our AFib patients with the latest advancements in cardiac treatments, including devices like the HeartLight X3 System,” said David N. Kenigsberg, MD, a clinical cardiac electrophysiologist and medical director of the electrophysiology laboratory at Westside Regional Medical Center in Plantation, Fla. “I am honored to be among the group of electrophysiologists helping to achieve the 10,000 patient HeartLight milestone and furthering the reach of this revolutionary technology.”
“CardioFocus values our partners and the leaders in the electrophysiology community who have made this noteworthy milestone a reality. Their collaboration and unwavering commitment to exceptional patient care have expedited the adoption of this technology at a remarkable pace,” said Burke T. Barrett, Chief Executive Officer & President at CardioFocus. “With more than 10,000 patients treated worldwide, we believe this is only the beginning, as CardioFocus is positioned to become a dominant force in the rapidly growing AFib ablation market with our proven HeartLight X3 System.”
